BioSpaceOriginal article
AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space
Phase 3negativeWainuaNegative
AI Analysis
Summary
AstraZeneca and Ionis' Wainua failed in a late-stage study of ATTR cardiomyopathy (ATTR-CM), casting doubt on competitors' next-generation candidates while potentially benefiting other companies in the space like BridgeBio and Intellia Therapeutics.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Wainua failed in late-stage study of ATTR-CM
Importance:7/10
Sentiment:
-0.70
ATTR-CMgene therapyclinical trial failurecompetitive impact
Read the original article
Published by BioSpace on July 10, 2026 12:26 PM